
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

January 24, 2005

TO: Examiner Maryam Monshipouri
Group 1652
571-272-0932

RECEIVED
CENTRAL FAX CENTER

JAN 24 2005

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (703) 872-9306

OF PAGES (incl. cover): 5

Re: U.S. Serial No. 10/760,407, filed January 21, 2004
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
THEREOF"
Atty. Docket No.: CL001306-DIVII

A Supplemental Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chunhua YAN et al.

Serial No.: 10/760,407

Filed: January 21, 2004

For: ISOLATED HUMAN KINASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING
HUMAN KINASE PROTEINS, AND USES
THEREOF

Art Unit: 1652

Examiner: M. Monshipouri

Atty. Docket: CL001306-DIVII

RECEIVED
CENTRAL FAX CENTER

JAN 24 2005

SUPPLEMENTAL PRELIMINARY AMENDMENTHonorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231*By Facsimile*

Sir:

This is in response to an Office Action mailed on December 22, 2004 from Examiner Monshipouri in which a further restriction requirement was issued for the above-referenced application.

By way of response, Applicants hereby elect claim group II, claims 3 and 31-43, directed to antibodies, etc., for examination and have canceled claims corresponding to the non-elected group IX.

Please amend the application as follows: